As Former White House Drug Czar Rahul Gupta revealed DEA intentional sabotage, will DEA Administrator Nominee Terrance Cole Address the Marijuana Crisis? Bureaucratic Inaction and Medical Delays Demand Accountability.
Read More
"The irony is glaring," said Boise. "The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability." The DEA's own 2025 National Drug Threat Assessment admits that illicit cannabis operations tied to foreign cartels thrive in legalized states, operating under state licenses while DEA policy bureaucrats Thomas Prevoznik and Matthew Strait remains unchecked.
Read More
Intelligent Waves' (IW) latest innovation in Human Performance Solutions, PeakNeuro™, is an AI-powered tool that uses audio neural entrainment to enhance cognitive function, improve sleep quality, accelerate learning, and sharpen focus. Crescenzo's presentation emphasized how this technology can help individuals recover from setbacks and rebuild stronger cognitive abilities, which are crucial for sustained growth in increasingly demanding life circumstances.
Read MoreInvestment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication
Read MoreRegenerative Medical Technologies Group, Inc. $RMTG, a regenerative medicine company, is pleased to announce that sales for its first quarter of 2025 surpassed $1.35M and achieved operational profits of $134,000 for the quarter.
Read MoreAs announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening
Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026
Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through PRIME and to Breakthrough Therapy designation in the US
Read More
The sam® sustained acoustic medicine device can help millions of people suffering from knee osteoarthritis to find relief, without invasive surgery or potentially addictive painkiller medications.
Read MoreTrial marks key milestone in driving pipeline progress
Phase 1 trial scheduled for completion mid-June 2025
Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback
Read MoreKey Regulatory Milestone Provides Clear Development Roadmap to Registration for MOTYS
Initiation of Phase 3 Program Remains on Schedule to Begin in Q3 2025
Company Updates Investor Presentation to Reflect Strong Q1 Earnings, More than $20M in Pro Forma Revenue and 15% Increase in 2025 Pro Forma Revenue Guidance
Read More
The appearance of Thomas Prevoznik and Matthew Strait as thought leaders in global drug policy is more than just tone-deaf-it's dangerous. It validates a failed regulatory approach that punishes innovation, undermines public health, and sidelines scientific progress for political convenience
Read More
AGFA HealthCare earns top-tier recognition for consistently delivering high-value imaging management solutions and services to healthcare organizations of all sizes.
Read MoreCrossTx Inc., a national leader in Medicare care management solutions, is proud to announce a strategic partnership with EverCare Mobile Health, Idaho's fast-growing mobile mental healthcare provider serving long-term care facilities across the region.
Read MoreEarly results show steroid-free remission, opening pathway into $13B global pet dental health market
VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy
Read MoreCompany reports quarterly revenue of $1.4 million; net loss and earnings per diluted Share of $6.6 million and $1.74
Quarterly adjusted EBITDA loss of $2.5 million reflects 29% YOY improvement
Stockholders' equity was $13.8 million at quarter end
Increases 2025 pro forma revenue guidance to more than $75 million based on strong first quarter across TRNR, Sportstech and Wattbike
Read More
"The DEA is creating a regulatory paradox where science is stifled and illegal activity is tolerated. Thomas Prevoznik, one unelected bureaucrat should not have the power to derail federally authorized drug development," said Duane Boise, CEO of MMJ International Holdings.
Read More
